Compare RWAY & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RWAY | SGHT |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.1M | 309.6M |
| IPO Year | 2015 | 2021 |
| Metric | RWAY | SGHT |
|---|---|---|
| Price | $6.69 | $8.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $9.50 | $9.08 |
| AVG Volume (30 Days) | ★ 587.0K | 251.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 21.54% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $1.26 | $11.67 |
| Revenue Next Year | $1.25 | $10.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.19 | $3.19 |
| 52 Week High | $10.92 | $9.24 |
| Indicator | RWAY | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 81.54 |
| Support Level | $6.43 | $8.00 |
| Resistance Level | $6.88 | $8.93 |
| Average True Range (ATR) | 0.20 | 0.52 |
| MACD | 0.08 | 0.22 |
| Stochastic Oscillator | 81.01 | 91.27 |
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.